Matinas BioPharma Holdings (MTNB) Return on Capital Employed (2014 - 2026)
Matinas BioPharma Holdings (MTNB) reported Return on Capital Employed of 157.42% for Q1 2026, up 4723.0% year-over-year from 3.26% in Q1 2025, and down 58.06% quarter-over-quarter from 99.59% in Q4 2025.
Matinas BioPharma Holdings (MTNB) Return on Capital Employed (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 13 years of Return on Capital Employed data on file, last reported at 157.42% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 157.42%, up 4723.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 157.42% (up 4723.0% YoY), and the FY2025 annual result was 82.25%, up 6949.0% from the prior year.
- Return on Capital Employed eased to 157.42% in Q1 2026 per MTNB's latest filing, from 99.59% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 47.65% in Q1 2022 and troughed at 204.65% in Q1 2025.
- A 5-year average of 107.44% and a median of 99.59% in 2025 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 7678 bps in 2025 and fell as far as 8636 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 58.69% in 2022, then sank by 63 bps to 95.73% in 2023, then plunged by 84 bps to 176.37% in 2024, then jumped by 44 bps to 99.59% in 2025, then slumped by 58 bps to 157.42% in 2026.
- Business Quant data shows MTNB's Return on Capital Employed at 157.42% in Q1 2026, 99.59% in Q4 2025, and 152.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - | -157.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -157.42% |
| Dec 31, 2025 | -99.59% |
| Sep 30, 2025 | -152.56% |
| Jun 30, 2025 | -167.24% |
| Mar 31, 2025 | -204.65% |
| Dec 31, 2024 | -176.37% |
| Sep 30, 2024 | -108.17% |
| Jun 30, 2024 | -121.26% |
| Mar 31, 2024 | -118.29% |
| Dec 31, 2023 | -95.73% |
| Sep 30, 2023 | -81.45% |
| Jun 30, 2023 | -67.61% |
| Mar 31, 2023 | -56.64% |
| Dec 31, 2022 | -58.69% |
| Sep 30, 2022 | -57.28% |
| Jun 30, 2022 | -55.91% |
| Mar 31, 2022 | -47.65% |
| Dec 31, 2021 | -41.36% |
| Sep 30, 2021 | -38.07% |
| Jun 30, 2021 | -34.39% |